Compositions useful for inhibiting HIV-1 infection and methods using same

1. A compound of formula (I), or a salt or solvate thereof:

wherein:

R 1 is

ring A is

wherein the atom labeled with A is linked to ring R 1 ;

linker L is selected from the group consisting of:

wherein the atom labeled with B is linked to ring B;

ring B is selected from the group consisting of:

each occurrence of R 2 is independently selected from the group consisting of —(C 1 -C 6 )alkyl, —(C 1 -C 6 )fluoroalkyl, —F, —Cl, —Br, —I, and —OR 7 ;

R 4 is 1,2,4-triazolyl optionally substituted with (C 1 -C 6 )alkyl;

R 5 is selected from the group consisting of H, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )fluoroalkyl, and —OR 7 ;

R 6 is H or F;

each occurrence of R 7 is independently selected from the group consisting of H and —(C 1 -C 6 )alkyl;

X is CH or N;

x is an integer from 0-5; and

each occurrence of n is independently 0 or 1.

2. The compound of claim 1 , wherein R 1 is

3. The compound of claim 1 , wherein the compound is N-(3-benzoyl-3-azabicyclo[3.1.0]hexan-6-yl)-3-(4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)-2,3-dioxopropanamide (SC28), or a salt, N-oxide or solvate thereof.

4. A pharmaceutical composition comprising at least one compound of claim 1 and at least one pharmaceutically acceptable carrier.

5. The composition of claim 4 , further comprising at least one additional therapeutic agent useful for treating an HIV infection.

6. The composition of claim 5 , wherein the at least one additional therapeutic agent comprises at least one selected from the group consisting of a HIV drug combination, entry and fusion inhibitor, integrase inhibitor, non-nucleoside reverse transcriptase inhibitor, nucleoside reverse transcriptase inhibitor, and protease inhibitor.

7. A method of treating an HIV-1 infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of at least one compound of formula (I):

wherein:

R 1 is

ring A is

wherein the atom labeled with A is linked to ring R 1 ;

linker L is selected from the group consisting of:

wherein the atom labeled with B is linked to ring B;

ring B is selected from the group consisting of:

each occurrence of R 2 is independently selected from the group consisting of —(C 1 -C 6 )alkyl, —(C 1 -C 6 )fluoroalkyl, —F, —Cl, —Br, —I, and —OR 7 ;

R 4 is 1,2,4-triazolyl optionally substituted with (C 1 -C 6 )alkyl;

R 5 is selected from the group consisting of H, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )fluoroalkyl, and —OR 7 ;

R 6 is H or F;

each occurrence of R 7 is independently selected from the group consisting of H and —(C 1 -C 6 )alkyl;

X is CH or N;

x is an integer from 0-5; and

each occurrence of n is independently 0 or 1;

a salt, solvate, or N-oxide thereof, and any combinations thereof.

8. The method of claim 7 , wherein R 1 is

9. The method of claim 7 , wherein the compound is N-(3-benzoyl-3-azabicyclo[3.1.0]hexan-6-yl)-3-(4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)-2,3-dioxopropanamide (SC28); or a salt, N-oxide or solvate thereof.

10. The method of claim 7 , wherein the method further comprises administering to the subject at least one additional therapeutic agent useful for treating HIV infection.

11. The method of claim 10 , wherein the at least one additional therapeutic agent comprises at least one selected from the group consisting of a HIV drug combination, entry and fusion inhibitor, integrase inhibitor, non-nucleoside reverse transcriptase inhibitor, nucleoside reverse transcriptase inhibitor, and protease inhibitor.

12. The method of claim 10 , wherein the compound and the at least one additional therapeutic agent are co-administered to the subject.

13. The method of claim 12 , wherein the compound and the at least one additional therapeutic agent are coformulated.

14. The method of claim 7 , wherein the subject is a mammal.

15. The method of claim 14 , wherein the mammal is human.